US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...

Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...

On October 23, Lilly and Mumbai-based Cipla announced a joint agreement to distribute and promote tirzepatide under the brand ...

Weight loss medications can be lifesaving for people who need them — but there are errors you’ll want to avoid.

SIGNIFICANT EVENTS DURING 1 JULY - 30 SEPTEMBER 2025During the third quarter, Iconovo carried out a reorganization to focus on the three largest near-term opportunities: ICOpre, ICOres, and the develo ...

"UK regulators seize illegal weight loss drugs amid global pricing shake-up" was originally created and published by ...

FDA Approves Novo Nordisk's oral semaglutide for cardiovascular (CV ... life-saving surgery on babies before and immediately ...

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

PORTIA Devine had struggled with her weight since she was a child – trapped in a painful cycle of emotional eating and low ...

Analysts believe that while the deal is positive, Cipla's share price is unlikely to see a fresh run-up, given the rise it ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.